# Critical Evaluation of Tau PTM Hypotheses
## Hypothesis 1: K280 Acetylation and Mitochondrial Trafficking
### Strongest Weakness: Causality Remains Unproven
The "bifunctional switch" framing implies K280 acetylation *causes* both microtubule destabilization and mitochondrial mislocalization, but the cited evidence (Cohen 2011) demonstrates correlation and overexpression artifact risk. K280Q/K280R mutants used to model acetylation/mimic deacetylation produce non-physiological tau conformations that may confound interpretation. Critically, mitochondrial transport deficits precede detectable K280 acetylation in some models, suggesting the modification may be a downstream marker rather than driver.
### Counter-Evidence and Complications
1. **Redundancy with phosphorylation**: K280 lies within R1 repeat domain. Phosphorylation at S262, a well-validated site for microtubule destabilization, produces similar microtubule-binding loss without requiring acetylation. Is K280 acetylation *necessary* when S262 phosphorylation can explain the same phenotype?
2. **Aging confounds**: K280 acetylation increases with normal aging in humans and animal models (Strong. 2020, PMID: 32868909). Does this represent pathologicalspecificity or physiological accumulation?
3. **p300 inhibitor specificity problem**: A-485 inhibits all p300/CBP-mediated acetylation. Any "preservation of mitochondrial distribution" outcome cannot be attributed to K280 specifically without measuring on-target engagement. CEP-10878 selectivity data remains proprietary/unpublished.
4. **Synaptic loss endpoint ambiguity**: "Ameliorate synaptic loss" in 3xTG-AD mice is a late-stage, multifactorial outcome. Does restored mitochondrial transport *directly* rescue synapses, or are there intermediate steps where the effect dissipates?
### Pointed Question
**If K280 acetylation is pharmacologically reduced to baseline but mitochondrial transport deficits persist in primary neurons from symptomatic 3xTG-AD mice, what is your mechanistic explanation? Specifically: does this falsify the hypothesis, or do you propose redundant pathways where K280 acetylation is one contributor among several?**
---
### Confidence Rating: **MODERATE**
The hypothesis is mechanistically specific, has credible supporting literature, and offers a falsifiable prediction. However, causality chains are implied rather than demonstrated. The "bifunctional" framing requires more evidence linking *both* functions to the same modification site in primary disease-relevant tissue.
---
## Hypothesis 2: AEP-Mediated Truncation at N368 (Fragment Incomplete)
### Strongest Weakness: Mechanism of Toxicity Is Unspecified
The hypothesis states truncation generates "neurotoxic tau fragments" but does not articulate *how* N368 truncation causes toxicity. Without this mechanistic link, the hypothesis risks circular reasoning: "AEP is activated in AD → cleaves tau at N368 → generates toxic fragment → causes toxicity." What is the toxic mechanism—aggregation seeding, membrane permeabilization, mitochondrial targeting, gain-of-function on synaptic proteins?
### Counter-Evidence and Complications
1. **Caspase competition**: Caspase-3 cleaves tau at D421, C-terminal to N368, generating Δtau421 fragment. This truncation also occurs in AD and is equally implicated in toxicity. Does N368 truncation act upstream, downstream, or independently of D421 cleavage? Temporal sequencing is unclear.
2. **AEP substrate promiscuity**: AEP/legumain cleaves numerous substrates including APP, α-syn